Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

Professor Prabhakar Rajan has spoken out about the concerning rate of prostate cancer diagnoses and the one thing he wants men to do to tackle it ...

Tests and screenings exist that help doctors detect these illnesses and take potentially life-saving action before the ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

By Capital Blue Cross New research shows just how powerful preventive cancer screenings can be. A recent analysis from the Blue Cross Blue Shield Association found that people who stay up to […] ...

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Many symptoms associated with prostate cancer, like frequent urination or difficulty peeing, may be caused by less-serious concerns. Learn more.

Researchers in Norway have uncovered new features that may help doctors tell the difference between slow-growing prostate cancer and the more dangerous aggressive type. The discovery could eventually ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...